CCI rules in favour of Biocon in case against Roche over breast cancer drug

Biocon and Mylan started marketing biosimilars of Roche's Trastuzumab drug in 2014

The Competition Commission of India (CCI) has given directions for carrying out a detailed investigation to ascertain if Roche used its dominant position to maintain its monopoly over the breast cancer drug Trastuzumab.  

The order comes as a response to a joint complaint filed by the Mylan and Biocon in 2016 alleging that the Roche Group indulged in "abusive conduct".

"The Commission is of the considered view that, prima facie, the contravention with regard to Section 4(2)(c) of the Act is made out against Roche Group, which warrants a detailed investigation into the matter. The DG is, thus, directed to carry out a detailed investigation into the matter", said the order.

Both Mylan and Biocon further alleged that the group tried to influence regulatory authorities to deny the sale of biosimilars of Trastuzumab by them. Roche had allegedly informed the regulators that biosimilars of Mylan and Biocon were hazardous to patients.

The group was further accused of affecting the entry of market players who sought the approval of requisite authorities for the launch of such biosimilars in the Indian market.

In 2002, Roche launched Trastuzumab under the brand name Herceptin in India marketing each 440 mg vial at Rs 1,20,000.

A campaign for Affordable Trastuzumab was launched in November 2012 and it demanded that the Government of India intervene to enable the production of biosimilars and ensure that the drug is made available to all.

Roche, subsequently, withdrew its Herceptin and launched the drug under the brand name Herclon and Biceltis (marketed by Emcure who distributed it) at a slightly lower price of Rs 75,000 for a 440 mg vial, which was still out of reach for most patients.

In 2013, after facing challenges to its patent claims, Roche chose to withdraw its patent in India in August 2013.

After obtaining requisite approvals from the regulators in 2013, Biocon and Mylan started marketing biosimilars of Trastuzumab under the brand names CANMAb and Hertraz in 2014. Roche filed a case against the regulators for issuing licenses to these companies for the said drug.

More recently, the Delhi High Court's Division bench in March upheld the Indian drug regulator's approval given to Biocon and Mylan to market their cancer drug during the pendency of the civil suit for all indications.

Trastuzumab is now included in the National List of Essential Medicines and a number of public sector entities such as the CGHS, Indian Railways either reimburse or procure the drug.

A majority of patients in India have to pay for Trastuzumab themselves and some have been seeking financial assistance from the PM's National Relief Fund to access the drug.

The price of Trastuzumab has dropped to range between Rs, 29,500 and Rs 33,000 per 440 mg vial and distributors are offering one vial free after a patient purchases three vials.

Source: http://www.business-standard.com/article/companies/cci-rules-in-favour-of-biocon-in-case-against-roche-over-breast-cancer-drug-117042501063_1.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more